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Antimicrobial resistance (AMR) is an area of grave concern globally,1 ;  2 reflected in 
the recent UN meeting on the subject to rally worldwide coordinated action to combat 
the AMR threat.3 A multipronged approach is required, including reduction in use of 
antibiotics in agriculture, better stewardship of antibiotics in human medicine, and 
encouraging development of new antibiotics. Margaret Chan, Director General of 
WHO commented that, “with few replacement products in the pipeline the world is 
heading to a post-antibiotic era in which common infections…will once again 
kill”.4 Efforts have started to encourage new antibiotic development, but there is a 
lack of recent evidence on the actual development pipeline. 
The National Institute for Health and Care Excellence (NICE) provides advice to the 
National Health Service (NHS) in England on new treatments. The National Institute 
for Health Research Horizon Scanning Research and Intelligence centre (NIHR 
HSRIC) undertakes horizon scanning on behalf of the NHS, including NICE. NICE 
and NIHR HSRIC have examined the future antibiotic pipeline to determine what 
agents could potentially receive marketing authorisation over the next 5 years. 
We identified 28 new antibiotic indications in development and potentially coming to 
market within the next 5 years, with a significant number active in high risk areas 
such as methicillin-resistant Staphylococcusaureus or vancomycin resistant 
enterococci (15), carbapenemase-producing Enterobacteriaceae (6), Clostridium 
difficile (4) and Gram-negative infections (9). At first glance, the quantity of new 
antibiotic indications appears reassuring; however, most (17) are not novel classes, 
but are rather next-generation agents derived from existing classes or new 
combinations of existing agents. Additionally, the 11 agents with novel mechanisms 
of action are not all active against high-risk systemic, urinary tract, or respiratory 
infections; four of 11 are indicated for skin or skin structure infections, and one is a 
topical agent for mildly infected diabetic foot ulcers. 
We support the accelerated development of new antimicrobials to combat AMR, but 
we believe that it is not sufficient to encourage antibiotic innovation in a broad-brush 
manner; we must accurately define the key gaps in our antibiotic armoury, and 
prioritise these areas for investment in research and development. This approach 
requires active cooperation between research institutions, health care economies, 
the pharmaceutical industry, and governments both nationally and internationally, as 
set out in the recommendations of the O'Neill review on antimicrobial resistance and 
the UN high-level meeting, which we fully support.3 ;  5 
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